REVIEW ARTICLE

Galectins and Gliomas

Marie Le Mercier1; Shannon Fortin1; Véronique Mathieu1; Robert Kiss1; Florence Lefranc1,2

1 Laboratory of Toxicology; Institute of Pharmacy, and 2 Department of Neurosurgery; Erasme University Hospital; Université Libre de Bruxelles (ULB), Brussels, Belgium.

Abstract

Malignant gliomas, especially glioblastomas, are associated with a dismal prognosis. Despite advances in diagnosis and treatment, glioblastoma patients still have a median survival expectancy of only 14 months. This poor prognosis can be at least partly explained by the fact that glioma cells diffusely infiltrate the brain parenchyma and exhibit decreased levels of apoptosis, and thus resistance to cytotoxic drugs. Galectins are a family of mammalian beta-galactoside-binding proteins characterized by a shared characteristic amino acid sequence. They are expressed differentially in normal vs. neoplastic tissues and are known to play important roles in several biological processes such as cell proliferation, death and migration. This review focuses on the role played by galectins, especially galectin-1 and galectin-3, in glioma biology. The involvement of these galectins in different steps of glioma malignant progression such as migration, angiogenesis or chemoresistance makes them potentially good targets for the development of new drugs to combat these malignant tumors.

Keywords
Galectin, Glioma, Migration, Angiogenesis, Resistance.

GLIOMAS: AN OVERVIEW

Gliomas account for more than 50% of all primary brain tumors and are by far the most common primary brain tumor in adults (71, 73, 77). Gliomas include tumors that are composed predominantly of astrocytes (astrocytomas), oligodendrocytes (oligodendrogliomas), ependymal cells (ependymomas) or a mixture of various glial cells (eg, oligoastrocytomas) (77). The World Health Organization grading system classifies gliomas into grade I to IV based on the degree of malignancy, as determined by histopathological criteria. Grade I gliomas are generally well circumscribed and behave in a benign fashion, whereas grade II through IV gliomas are malignant and diffusely infiltrate the brain (77). Among gliomas, astrocytomas are the most common and are comprised of pilocytic astrocytomas (grade I), diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) and glioblastoma (grade IV) (77). Glioblastomas are characterized by a very dismal prognosis (74, 113). Glioblastoma patients have a median survival expectancy of only 14 months when on the current standard treatment of surgical resection to the extent feasible, followed by adjuvant radiotherapy plus temozolomide chemotherapy, given concomitantly with and after radiotherapy (73, 74, 87).

Malignant gliomas are associated with such dismal prognoses because glioma cells can actively migrate through the narrow extracellular spaces in the brain, often traveling relatively long distances, making them elusive targets for effective surgical management (16, 33, 47, 71). Additionally, after surgical resection and adjuvant treatment of malignant gliomas, the residual cancer cells peripheral to the excised lesion give rise to a recurrent tumor that in more than 90% of cases develops immediately adjacent to the resection margin (33, 46, 71).

Clinical and experimental data have also demonstrated that invasive malignant glioma cells show a decrease in proliferation rate and a relative resistance to apoptosis as compared with the highly dense cellular center of the tumor, and this may contribute to their resistance to conventional pro-apoptotic chemotherapy and radiotherapy (33, 46, 71, 72). One way to potentially overcome resistance to apoptosis is to decrease the migration of malignant glioma cells in the brain, which should then theoretically restore a level of sensitivity to cytotoxic drugs (54, 64, 72, 82).

GALECTINS: AN OVERVIEW

Galectins are a structurally related family of animal lectins defined by two properties: (i) an affinity for β-galactoside sugars; and (ii) a sequence homology (2, 3, 19, 75). This consensus sequence corresponds to the carbohydrate-recognition domain (CRD), which is a beta sandwich of about 135 amino acids long and is responsible for β-galactoside binding (2, 3, 19, 75). To date 15 galectins have been characterized; they are numbered according to the chronology of
their discovery (galectin-1 to galectin-15) (2, 3, 19, 75). The galectins known so far have either one or two CRDs within a single polypeptide chain, and each CRD is not associated with other types of well-defined protein domains. The mono-CRD galectins can be biologically active as monomers (galectin-5, -7, -10) or as homodimers (galectin-1, -2, -11, -13, -14, -15); the bi-CRD galectins (galectin-4, -6, -8, -9, 12) are active as monomers and might also associate into oligomers (69, 70). Galectin-3, a mono-CRD galectin, is unique in that it contains a short proline, glycine and tyrosine rich N-terminal domain fused onto the CRD that therefore allows the formation of oligomers (69, 70). Galectins show a high level of evolutionary conservation, whereby members of this family are present in organisms from nematodes to mammals (49).

Galectins can segregate into multiple cell compartments. Although these proteins lack the signal sequence that would be required for secretion through the classical secretory pathway, some galectins show extracellular localization, suggesting that they are secreted through a non-classical pathway (51, 92, 116). Galectins are present both inside and outside cells. They function extra-cellularly by interacting with cell surface and extracellular matrix (ECM) glycoproteins and intracellularly by interacting, in a carbohydrate-independent manner, with cytoplasmic and nuclear proteins (24, 42, 75, 101). They play a role in a wide range of processes, including cell adhesion, regulation of cell growth, apoptosis, embryonic development and immune processes-like inflammation (13, 24, 43, 44, 75, 88, 97, 101, 114).

A large amount of experimental evidence has been reported to support the important roles of galectins in cancer biology (19, 23, 24, 75, 115), including tumor angiogenesis (56, 65, 123–125), tumor immune escape (96, 106, 112) and cancer cell migration (35, 45, 53, 86, 134). In the current review, we focus our attention on the biological roles exerted by galectins in gliomas.

**GALECTINS THAT COULD BE IMPLICATED IN GLIOMA BIOLOGY**

The group of A. Raz was among the first to demonstrate a relationship between galectin expression and the malignant potential of tumors in the central nervous system (9). Indeed, they have shown that the expression level of galectin-3 was significantly associated with astrocytic tumor grade (9). In contrast, Gordower et al found that the level of galectin-3 expression significantly decreases in the majority of astrocytic tumors from low to high grade. However, they also observed that some highly malignant tumor cell clones expressed high amounts of galectin-3 (36). Numerous other studies have also confirmed that astrocytic tumors express high levels of galectin-3 (61, 91, 119, 121, 122). With regard to the other types of glioma, Bressailler et al have reported that galectin-3 was not expressed in oligodendrogliomas or ependymomas (9). In another study, galectin-3 expression was shown to be significantly higher in glioblastomas and pilocytic astrocytomas than in oligodendrogliomas, anaplastic oligodendrogliomas, and diffuse astrocytomas (91). Finally, it was reported that galectin-3 was expressed in oligodendrocytes, endothelial cells and macrophages/microglial cells in areas of solid tumor growth (22). In this study, Deininger et al showed that significantly fewer galectin-3 positive oligodendroglialoma cells and macrophages/microglial cells were detected in grade II oligodendrogliomas than in grade III anaplastic oligodendroglomas. On the contrary, significantly more galectin-3 positive endothelial cells were detected in grade II than in grade III oligodendroglomas (22). Moreover, in an attempt to reconcile the conflicting results published on galectin-3 expression in human gliomas, Strik et al have used immunohistochemistry to identify the cellular origin and extent of galectin-3 positivity in glioma samples (119). They have shown in this study that galectin-3 was expressed in neoplastic astrocytes, macrophages/microglial cells, endothelial cells and some B- and T-lymphocytes. They also pointed out that galectin-3 positivity was considerably influenced by tumor-infiltrating macrophages (119). The expression level of galectin-3 seems then to be highly dependent on non-tumor cells such as endothelial cells or macrophages/microglial cells. This feature can thus partly explain the conflicting results that have been published on galectin-3 expression in human gliomas (22, 119).

The role of galectin-1 in glioma biology was first suggested by Yamaoka et al (131) and Gunnersen et al (39). They have analyzed the mRNA expression of galectin-1 by northern blot in glioma specimens and glioma cell lines. Increased expression of galectin-1 mRNA was shown to correlate with increased malignancy in human astrocytic tumors ranging from low-grade astrocytomas to malignant gliomas (131). However, no statistical analysis was made (131). Two studies from our own group using clinical samples have shown that galectin-1 is expressed in all glioma types and that the level of galectin-1 expression correlates directly with the grade of the astrocytic tumor (10, 105). Specifically, we quantitatively determined (by computer-assisted microscopy) the immunohistochemical expression of galectin-1 in 220 gliomas, including 151 astrocytic, 38 oligodendrogial and 31 ependymal tumors (105). Our data revealed the expression of galectin-1 in all human glioma types with no striking variation in levels among astrocytic, oligodendrogial and ependymal tumors; the level of galectin-1 expression within astrocytic tumors, however, significantly correlated with tumor grade (105). Furthermore, expression levels of galectin-1 in high-grade astrocytic tumors from patients with short-term survival periods were significantly higher than those in tumors from patients with long-term survivals (105).

Very little is known about the expression of other galectins in brain tumors. A reverse transcription polymerase chain reaction analysis has shown that galectin-1, -2, -4, -7, -8 and -9 are expressed in normal human brain (111). In another study, Lahm et al have examined the expression of a panel of galectins, including galectin-1, -2, -3, -4, -7, -8 and -9, in eight glioma cell lines (62). Galectin-1, -3 and -8 were the most abundantly expressed in all the cell lines. Galectin-2 was expressed in only one cell line, galectin-4 and -9 were expressed weakly in three cell lines, and no evidence for the presence of galectin-7 mRNA was found among any of the cell lines (62).
THE INTERACTIONS BETWEEN GALECTINS AND INTEGRINS

Galectins are components of the ECM. The ECM comprises all secreted soluble and insoluble molecules found within the extracellular fluid of the extracellular space. The ECM is not only a static scaffolding for tissue organization but it is involved as well in many regulatory functions like modulation of migration, guidance of axonal growth, synapse formation and cell proliferation. Several reviews have already addressed an in-depth analysis of glioma ECM. We thus cite these reviews without commenting on them, keeping in mind that the current review aims to analyze the roles of galectins in glioma biology. These reviews include the pioneering work of J.T. Rutka (107–109) among others (5, 15, 34, 47, 63, 71, 87, 103, 129).

As emphasized by Uhm et al (127), integrins are cell-surface receptors that mediate the physical and functional interactions between a cell and its surrounding ECM. Integrins consist of two non-covalently associated transmembrane glycoprotein subunits, alpha and beta, both of which contribute to the binding of ECM components. To date 18 different alpha-subunits and 8 different beta-subunits have been identified, which associate to form 25 recognized alpha/beta heterodimers (48). The specific alpha or beta chains that constitute the integrin receptor determine the repertoire of ECM proteins to which a specific integrin may bind. Moreover, many integrin ligands exhibit a specific three-amino acid sequence labeled arginine–glycine–aspartate (RGD), a sequence that is present in most ECM components (48). Although classically the role ascribed to integrins has been that of anchoring cells to the ECM, the functions of integrins greatly exceed that of mere cell adhesion (127). Within this multifaceted role, integrins have been shown to be molecular determinants of glioma invasion (5, 6, 18, 90, 110).

Galectins and integrins closely interact when modulating cell adhesion and/or cell migration. For example, Moiseeva et al have shown that galectin-1 interacts with the integrin beta1 subunit in vascular smooth muscle cells (85) (Figure 1). Via its direct binding to beta1 integrins (without cross-linking), dimeric galectin-1 induces expression of RhoA and the alteration of the polymerization of the actin cytoskeleton (11) Once again, the receptor to which Gal-1 bind to initiate this signaling is not known. Galectin-3 (Ga-3) regulates cell adhesion via binding to alpha5beta1 (94). Ga-3 also forms a complex with alpha2beta1 and the proteoglycan NG2 (31). This interaction regulates endothelial cell motility and angiogenesis. Finally, Ga-3 has been shown to regulate the expression of integrin alpha6beta1 and actin cytoskeleton organization (20). However, it is not known with which molecule(s) Gal-3 is interacting to initiate this signaling. Galectin-8 (Gal-8) interacts with several integrins including alpha1beta1, alpha3beta1, alpha5beta1 and alpha6beta1. These interactions are involved in cell adhesion and apoptosis (40). Abbreviations: ERK = extracellular signal-regulated kinase; FAK = focal adhesion kinase; MEK = MAP kinase/ extracellular signal-regulated kinase kinase (MAPK/ERK Kinase); PKCe = protein kinase C epsilon.
the amount of partially activated β1 integrins, but does not induce dimerization with α subunits (85). In the case of vascular smooth muscle cells, this interaction of galectin-1 with α1β1 integrin has been reported to both transiently phosphorylate focal adhesion kinase and modulate cell attachment, spreading and migration on laminin, but not on cellular fibronectin (38, 85). Thus galectin-1 is likely to affect smooth muscle cell adhesion by interacting with β1 integrin on the cell surface and inducing outside-in signaling (85) (Figure 1).

Galectin-1 also interacts with α5β1 integrin to restrict epithelial tumor cell growth (26) (Figure 1). Indeed, Fischer et al. have observed that the anti-proliferative potential of galectin-1 with α1β1 integrin has been reported to both transiently phosphorylate focal adhesion kinase and modulate cell attachment, spreading and migration on laminin, but not on cellular fibronectin (38, 85). Thus galectin-1 is likely to affect smooth muscle cell adhesion by interacting with β1 integrin on the cell surface and inducing outside-in signaling (85) (Figure 1).

Galectin-1 also interacts with α5β1 integrin to restrict epithelial tumor cell growth (26) (Figure 1). Indeed, Fischer et al. have observed that the anti-proliferative potential of galectin-1 with α1β1 integrin has been reported to both transiently phosphorylate focal adhesion kinase and modulate cell attachment, spreading and migration on laminin, but not on cellular fibronectin (38, 85). Thus galectin-1 is likely to affect smooth muscle cell adhesion by interacting with β1 integrin on the cell surface and inducing outside-in signaling (85) (Figure 1).

Galectin-1 expression is stimulated by hypoxia via HIF-1 (132) and stimulates angiogenesis in vitro and in vivo (89). Gal-3 has also been shown to interact with NG2 proteoglycan, a component of microvasculature pericytes, which stimulates endothelial cell motility and morphogenesis (130). In addition, Gal-3 is involved in chemoresistance, a process that is increased in hypoxic conditions (30). Galectin-1 (Gal-1) expression is also stimulated in hypoxic conditions (67), however, it is not known if this is HIF-1-dependent. Recent evidence indicates that Gal-1 plays an important role in angiogenesis and in chemo- and radioresistance (64, 120). These effects of Gal-1 can be explained at least partly by the fact that Gal-1 modulates the unfolded protein response (UPR), a process that is involved in resistance and angiogenesis (64, 65). Moreover, Gal-1 was shown to control the expression level of the UPR-regulated protein ORP150, which is responsible for vascular endothelial growth factor (VEGF) maturation and secretion (65).

Figure 2. Presumed role of galectins in angiogenesis and chemoresistance. Necrotic foci in glioblastoma are typically surrounded by hypercellular zones referred to as pseudopalisades (104). It has been shown that pseudopalisades are hypoxic and express high amounts of the transcription factor hypoxia-inducible factor 1 (HIF-1) (104). Galectin-3 (Gal-3) expression is stimulated by hypoxia via HIF-1 (132) and stimulates angiogenesis in vitro and in vivo (89). Gal-3 has also been shown to interact with NG2 proteoglycan, a component of microvasculature pericytes, which stimulates endothelial cell motility and morphogenesis (130). In addition, Gal-3 is involved in chemoresistance, a process that is increased in hypoxic conditions (30). Galectin-1 (Gal-1) expression is also stimulated in hypoxic conditions (67), however, it is not known if this is HIF-1-dependent. Recent evidence indicates that Gal-1 plays an important role in angiogenesis and in chemo- and radioresistance (64, 120). These effects of Gal-1 can be explained at least partly by the fact that Gal-1 modulates the unfolded protein response (UPR), a process that is involved in resistance and angiogenesis (64, 65). Moreover, Gal-1 was shown to control the expression level of the UPR-regulated protein ORP150, which is responsible for vascular endothelial growth factor (VEGF) maturation and secretion (65).

Galectin-3 was also shown to bind to α1β1 integrin and it was suggested that this interaction regulates cell adhesion of various tumor cell lines by preventing α1β1 integrin interaction with the ECM proteins (94) (Figure 1). Galectin-3 also forms a complex with α3β1 integrins and NG2 on the surface of endothelial cells. The subsequent transmembrane signaling via α3β1 has been shown to be responsible for endothelial cell motility and angiogenesis (31) (Figures 1 and 2).

Finally, galectin-8 was also reported to interact with a subgroup of integrins that include α3β1, α6β1, and to a lesser extent with the α4 and the β3 subunits in human carcinoma (1299) cells (40). These interactions were shown to inhibit cell adhesion and to induce apoptosis (40). More recently, galectin-8 was shown to bind α1β1, α3β1 and α5β1 integrins in Jurkat T cells (14) (Figure 1).

As the aforementioned indicates, integrins are known to play a significant role in the malignant progression of cancer cell through their involvement in cell adhesion, motility and intracellular signaling (1, 41, 52), with an emphasis on the role of the beta 1 integrin subunit in gliomas (4, 6, 18, 95). As galectins bind integrins, with galectin-1, galectin-3 and galectin-8 all known specifically to...
modulate β1 integrin function, the understanding of molecular mediators such as galectins and the pathways through which they drive the cell invasion so descriptive of glioblastoma multiforme (GBM) is anticipated to reveal potential therapeutic targets that promote glioma malignancy (28). Indeed, targeting both integrins and galectins represents a feasible proposition in the future treatment of gliomas; already there is evidence amounting that attests to this. For example, the small α5β1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells (78). Moreover, impairing galectin-1 expression in vivo in experimental gliomas through the delivery of anti-galectin-1 siRNA augments the therapeutic benefits contributed by temozolomide (65).

**GALECTINS AND GLIOMA CELL MIGRATION**

Cell migration involves at least three independent but highly coordinated biological processes: (i) cell adhesion to numerous components of the ECM; (ii) cell motility, which involves the reorganization of the actin cytoskeleton mainly through modification of the components of the adhesion complex; and (iii) invasion that involves the degradation of matrix proteins by tumor-secreted proteolytic enzymes, mainly serine proteases, cathepsins and metalloproteinases (MMPs) (21, 71, 103).

Galectins are involved in each of these steps (118). For example, galectin-1, galectin-3 and galectin-8 have been shown to influence glioma cell migration (10) (Figure 1). The expression of these galectins was shown to be higher in the invasive parts of xenografted glioblastomas than in the less invasive parts, suggesting their involvement in tumor astrocyte invasion of the brain parenchyma (10). In addition, galectin-1, galectin-3 and to a lesser extent galectin-8, markedly stimulate the migration of glioma cell lines (U373 and U87) in vitro (10) (Table 1). Moreover, galectin-3 biological functions were reported to be modulated by MMPs (93, 94), which play crucial roles in glioma cell motility and invasion (103). McClung *et al* (81) have shown by cDNA array analysis that secreted protein acidic and rich in cysteine, which is highly expressed in human gliomas and promotes glioma invasion, upregulates membrane type 1-matrix MMP and matrix MMP-2 transcripts, coincident with both increases in secreted galectin-3 and the proteolytically processed form of galectin-3. This concurrent stimulation of MMPs and galectin-3 supports a role for galectin-3 in glioma motility. However, in disagreement with the aforementioned, cultured galectin-3 deficient U373 glioblastoma cells, obtained by a stable transfection with a specific expression antisense plasmid, have been shown to both have increased motility potential on laminin and display modifications in cytoskeleton reorganization (20) (Table 1, Figure 1). c-DNA microarrays and quantitative immunofluorescence analysis showed that these

### Table 1. Biological functions of galectins in gliomas. Abbreviation: CRD = carbohydrate-recognition domain.

| Galectins    | Structures               | Cell types expressing and influenced by galectins in glioma context | Biological functions in gliomas | Presumed mechanism of action in glioma context                                                                 | Intracellular (IC) or extracellular (EC) role | References |
|--------------|--------------------------|-----------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------|------------|
| Galectin-1   | Mono-CRD                 | Astrocytes, Oligodendrocytes, Ependymocytes, Endothelial cells, Perivascular cells | Cell migration                  | • Modulation of cytoskeleton organization<br>• Modulation of RhoA expression<br>• Modulation of ADAM-15 expression<br>• Modulation of integrin β1 recycling | EC (111)                                      |            |
|              |                          |                                                                       | Angiogenesis                    | • Regulation of VEGF secretion via the regulation of ORP150 expression                                         | Unspecified                                   | (17, 65, 123) |
|              |                          |                                                                       | Chemo-/ Radioresistance         | • Regulation of the endoplasmic reticulum stress response<br>• Modulation of p53 transcriptional activity        | Unspecified                                   | (64, 120)  |
| Galectin-3   | Mono-CRD with an N-terminal domain | Astrocytes, Oligodendrocytes, Endothelial cells, Perivascular cells, Macrophages/microglial cells | Cell migration                  | • Modulation of cytoskeleton organization<br>• Modulation of integrins-α6 and -β1 expression                  | Unspecified                                   | (20)       |
|              |                          |                                                                       | Angiogenesis                    | • Interaction with NG2 proteoglycan on pericytes                                                            | EC                                            | (36, 89)   |
| Galectin-8   | Bi-CRD                   | Astrocytes, Perivascular cells                                       | Cell migration                  | Unknown                                                                                                    | EC                                            | (10)       |

© 2009 The Authors; Journal Compilation © 2009 International Society of Neuropathology
Galectins and Gliomas

Le Mercier et al

Glioma, Hypoxia, Angiogenesis and Galectins

Progression-associated genetic alterations are common to different glioma types, and target growth-promoting and cell-cycle control pathways resulting in focal hypoxia, necrosis and angiogenesis (76). GBM is distinguished pathologically from lower grade tumors by necrosis and microvascular hyperplasia (76). Necrotic foci are typically surrounded by “pseudopalisading” cells—a configuration that is relatively unique to malignant gliomas and has long been recognized as an ominous prognostic feature (Figure 2) (76, 104). Recent investigations have demonstrated that pseudopalisades are severely hypoxic, overexpress hypoxia-inducible factor 1 (HIF-1), and secrete proangiogenic factors such as vascular endothelial growth factor (VEGF) and IL-8 (104) (Figure 2). Pseudopalisades could represent a wave of tumor cells actively migrating away from central hypoxia that arises after a vascular insult (104). HIF-1 is one of the master regulators that orchestrate the cellular responses to hypoxia; it is a heterodimeric transcription factor composed of alpha and beta subunits (58). The alpha subunit is stable in hypoxic conditions but is rapidly degraded in normoxia; upon stabilization or activation, HIF-1 translocates to the nucleus and induces transcription of its downstream target genes (58). Most relevant to gliomagenesis, HIF-1 is a potent activator of angiogenesis and invasion through its upregulation of target genes critical for these functions; activation of the HIF-1 pathway is a common feature of gliomas and may explain the intense vascular hyperplasia often seen in GBM (27, 32, 58).

The expression of galectin-3, which is the most extensively studied member of the galectin family in the field of angiogenesis (89, 125) and with specific regard to gliomas (36, 130) (Table 1), has been shown to be stimulated upon HIF-1 activation (37, 50, 117, 132) (Figure 2). It has been shown that galectin-3 promotes chemotaxis and morphogenesis of endothelial cells and stimulates capillary tube formation in human umbilical vein endothelial cells in vitro (89). Moreover, galectin-3 was also reported to stimulate angiogenesis in vivo in breast cancer cell lines injected subcutaneously into the dorsolateral region of nude mice (89). Galectin-3 was also shown to interact with NG2 proteoglycan, a component of microvascular pericytes, which stimulates endothelial cell motility and morphogenesis. This function of NG2 on cell motility and morphogenesis depends on the formation of a complex with galectin-3 and α5β1 integrin to stimulate integrin-mediated transmembrane signaling (31, 130) (Figure 2).

Galectin-1 is also a hypoxia-regulated protein (7, 67, 68) that has been shown recently to display major roles in angiogenesis (17, 123), in both gliomas (65) (Table 1) and melanomas (80) (Figure 2). Galectin-1 involvement in tumor angiogenesis was first suggested after the discovery that both vascular smooth muscle and endothelial cells express the protein (84). Clausse et al had also previously shown that galectin-1 was upregulated in capillaries associated with carcinoma cells and found that galectin-1 could mediate interactions between tumors and endothelial cells in vitro, suggesting a potential role for galectin-1 in modulating angiogenesis (17). Finally, Thijssen et al have shown that both treatment with galectin-1 specific antisense oligodeoxynucleotides or with polyclonal anti-galectin-1 antibodies resulted in inhibition of endothelial cell proliferation and migration, demonstrating an essential role for galectin-1 during angiogenesis (123). The role of galectin-1 in tumor angiogenesis is further highlighted in galectin-1-null mice, in which tumor growth is markedly impaired because of insufficient tumor angiogenesis (123).

We ourselves have also put forward evidence for the role of galectin-1 in the process of angiogenesis using human glioma cells. To determine how galectin-1 exerts its pro-angiogenic effects, we investigated galectin-1 signaling in the human HS683 glioma cell line. We observed that galectin-1 signals through the endoplasmic reticulum transmembrane kinase/ribonuclease inositol-requiring alpha (IRE1alpha) that regulates the expression of oxygen-regulated protein 150 (ORP150), which in turn controls VEGF maturation (Figure 2). Galectin-1 also modulates the expression of six other hypoxia-related genes (ie, CTGF, ATF3, PPP1R15A,
glioma cell adhesion, motility and invasive features (66). This decrease in BEX2 expression impairs vasculogenic mimicry brain expressed X-linked gene (BEX2), a feature which confers

generated siRNA provokes a marked decrease in the expression of the
galactin-1 expression in Hs683 human glioma cells through tar-

Moreover, we have recently reported that downregulating

galactin-1 expression including DDIT3/GADD153/CHOP, DUSP5, ATF3 and GADD45A (64). In addition the decrease in galectin-1

expression impairs the ER stress response, which is believed to play

a role in drug resistance (79), and also impairs the expression levels of seven other genes implicated in chemoresistance: ORP150; HERP; GRP78/Bip; TRA1; BNIP3; GADD45B; and CYR61, some of

which are also known to be modified by hypoxia (64).

Similar to galectin-1, galectin-3 is also a hypoxia-regulated

protein (37, 50, 117, 132) that is implicated in cancer drug resis-
tance (29, 30) (Figure 2). Galectin-3 confers chemoresistance to a

wide variety of cancer cell types (30). Recent studies have revealed

that galectin-3 demonstrates anti-apoptotic effects, which contrib-

ute to cell survival in several types of cancer cells (88). In particular,
intracellular galectin-3, which contains the NWGR anti-death

motif of the Bcl-2 family, inhibits cell apoptosis induced by chemo-

therapeutic agents such as cisplatin and etoposide in some types of

cancer cells (88). It has also been reported that the nuclear export of

phosphorylated galectin-3 regulates its anti-apoptotic activity in

response to chemotherapeutic drugs. Indeed anticancer drugs can

induce DNA damage, which causes phosphorylated galectin-3 to

translocate from the nucleus to the cytoplasm and regulates phos-

phorylation of Bad, Akt and extracellular signal-regulated kinase

resulting in stabilization of mitochondrial membrane integrity. The

stabilization of the mitochondrial membrane prevents cytochrome

c release and subsequent caspase activation, resulting in the

suppression of apoptosis and anticancer drug resistance (30). Finally, it

has been suggested that targeting galectin-3 could improve the

efficacy of anticancer drug chemotherapy in several types of cancer

(30). However, the involvement of galectin-3 in the chemo- and/or

radioresistance of gliomas has not yet been demonstrated, at least to

the best of our knowledge.

CONCLUSIONS

Galectins are known to play an important role in cancer malignant

progression (75). Specifically, galectin-1, galectin-3 and to a lesser

extent galectin-8 have been reported to be implicated in glioma

malignant progression (Table 1). Galectin-1 especially is involved in

many different steps of tumor biology, such as migration, angiogen-

esis and resistance to chemotherapy and radiotherapy. More-

over, galectin-1 is also involved in tumor immune escape, however

not in gliomas (96, 102). Although there is much to learn about the

actual mechanisms by which galectins influence glioma cell

biology and much to explain regarding some conflicting results

obtained in different studies, the data reviewed here may be

amenable to therapeutic manipulation. We have already shown

that decreasing galectin-1 expression in human GBM orthotopic

xenografts in mouse brains by siRNA administration enhances the

therapeutic benefits of temozolomide (65). Thus, galectins and

especially galectin-1 could be important targets for the develop-

ment of new anticancer drugs not only for gliomas but for other

types of cancer as well (53, 100).
ACKNOWLEDGMENTS

M. Le Mercier is the holder of a Grant Télévie from the Fund for Scientific Research (FNRS) and S. Fortin is the holder of a Fulbright Grant. V. Mathieu is a postdoctoral researcher supported by the Fonds Yvonne Boël (Brussels, Belgium). F. Lefranc is a clinical research fellow and R. Kiss a director of research with the Belgian National FNRS (Belgium). The present manuscript was supported by grants awarded by the Fonds de la Recherche Scientifique Médicale (FRSM, Belgium) and by the Fonds Yvonne Boël (Brussels, Belgium).

REFERENCES

1. Aplin AE, Howe AK, Juliano RL (1999) Cell adhesion molecules, signal transduction and cell growth. Curr Opin Cell Biol 11:737–744.
2. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T et al (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76:597–598.
3. Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810.
4. Bartik P, Maglott A, Entlicher G, Vestweber D, Takeda K, Martin S, Domenwill M (2008) Detection of a hypersialylated betal integrin endogenously expressed in the human astrocytoma cell line A172. Int J Oncol 32:1021–1031.
5. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36:1046–1069.
6. Belot N, Norive S, Doyen I, Lefranc F, Bruyneel E, Dedecker R et al (2001) Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 36:375–390.
7. Boraldi F, Annoi G, Carraro F, Naldini A, Tiozzo R, Sommer P, Quaglino D (2007) Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 10:317–325.
8. D’Abaco GM, Kaye AH (2007) Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14:1041–1048.
9. Danguy I, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293.
10. Debray C, Verecpeen P, Belot N, Teillard P, Brion JP, Pandolfo M, Pochet R (2004) Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 325:1393–1398.
11. Decaestecker C, Debeir O, Van Ham P, Kiss R (2007) Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative assessment of cell migration. Med Res Rev 27:149–176.
12. Deininger MH, Trautmann K, Meyermann R, Schluesener HJ (2002) Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. Anticancer Res 22:1585–1592.
13. Demetter P, Nagy N, Martin B, Mathieu A, Dumont P, Decaestecker C, Salmon I (2008) The galectin family and digestive disease. J Pathol 215:1–12.
14. Eloba LT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64:1679–1700.
15. Eto K, Puzon-McLaughlin W, Sheppard D, Sehara-Fujisawa A, Zhang XP, Takada Y (2000) RGD-independent binding of integrin alpha5beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J Biol Chem 275:34922–34930.
16. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, Andre S et al (2005) Galectin-1 interacts with the [alpha]5[beta]1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 280:37266–37277.
17. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310.
18. Fortin S, Le Mercier M, Camby I, Spiegel-Kreinecker S, Berger W, Lefranc F, Kiss R (2008) Galectin-1 is implicated in the protein Kinase C epsilon/Vimentin-controlled trafficking of integrin-beta1 in Glioblastoma cells. Brain Pathol In Press.
19. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Sakai T, Kasai T, Andre S et al (2006) Galectin-3 regulates mitochonndrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66:3114–3119.
20. Fukushima T, Kanayama HO, Raz A (2007) The role of galectin-3 in cancer drug resistance. Drug Resist Updat 10:101–108.
21. Fukushima J, Makagiansar IT, Stalcup WP (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 15:5380–5390.
22. Gagner JP, Law M, Fischer I, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol 15:342–363.
33. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624–1636.
34. Gladson CL (1999) The extracellular matrix of gliomas: modulation of cell function. J Neuropath Exp Neurol 58:1029–1040.
35. Goetz JG, Joshi B, Lajoie P, Strugnell SS, Scudamore T, Kojic LD, Nabi IR (2008) Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveloin-1. J Cell Biol 180:1261–1275.
36. Gordon L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M et al (1999) Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumors and related angiogenesis. Neuropathol Appl Neurobiol 25:319–330.
37. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA et al (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206:291–304.
38. Gu M, Wang W, Song WK, Cooper DN, Kaufman SJ (1994) Selective modulation of the interaction of alpha 7 beta 1 integrin with fibronectin and laminin by L-14 lectin during skeletal muscle differentiation. J Cell Sci 107:175–181.
39. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS (2000) Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 32:146–154.
40. Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y (2000) Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci 113:2385–2397.
41. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70.
42. He J, Baum LG (2006) Galectin interactions with extracellular matrix and effects on cellular function. Methods Enzymol 417:247–256.
43. Hernandez JD, Baum LG (2002) Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 12:127R–136R.
44. Hirashima M, Kashiyo Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T et al (2004) Galectin-9 in physiological and pathological conditions. Glycoconjug J 19:593–600.
45. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I et al (2003) Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 103:370–379.
46. Hoellerzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, He J, Baum LG (2006) Secretion of the galectin family of mammalian integrins by human glioblastoma multiforme cells. J Cell Biol 170:761–771.
47. Hoellerzinger DB, Demuth T, Berens ME (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Nail Cancer Inst 99:1583–1593.
48. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100.
49. Houzelstein D, Goncalves IR, Faddjen AJ, Sidhu SS, Cooper DN, Drickamer K et al (2004) Phylogenetic analysis of the vertebrate galectin family. Mol Biol E 21:1177–1187.
50. Hu R, Jin H, Zhou S, Yang P, Li X (2007) Proteinomic analysis of hypoxia-induced responses in the syncytization of human placental cell line BeWo. Placenta 28:399–407.
51. Hughes RC (1999) Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1473:172–185.
52. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673–687.
53. Ingram L, Camby I, Lefranç F, Mathieu V, Nshimyumukiza P, Darro F, Kiss R (2006) Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13:3513–3527.
54. Ingriassia L, Nshimyumukiza P, Dewelle J, Lefranç F, Wlodarczak L, Thomas S et al (2006) A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J Med Chem 49:1800–1807.
55. Jensen RL (2006) Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 20:E24.
56. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC et al (2007) Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 9:662–670.
57. Jung TY, Jung S, Ryu HH, Jeong YI, Jin YH, Jin SG et al (2008) Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 109:273–284.
58. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134–153.
59. Kim HR, Lin HM, Biliran H, Raz A (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59:4148–4154.
60. Koumenis C (2006) ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6:55–69.
61. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S et al (2000) Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res 60:45–57.
62. Lahm H, Andre S, Hoefflich A, Fischer JR, Sordat B, Kaltner H et al (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127:375–386.
63. Lakka SS, Gondi CS, Rao JS (2005) Proteases and glioma angiogenesis. Brain Pathol 15:327–341.
64. Le Mercier M, Lefranç F, Mijatovic T, Deberi O, Haibe-Kains B, Bontempi G et al (2008) Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229:172–183.
65. Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C et al (2008) Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67:456–469.
66. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B et al (2009) Galectin-1-pro-angiogenic and pro-migratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia In Press.
67. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY et al (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23:8932–8941.
68. Le QT, Kong C, Lavori PW, O’Byrne K, Erler JT, Huang X et al (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167–175.
69. Leffler H (2001) Galectins structure and function—a synopsis. Results Probl Cell Differ 33:57–83.
70. Leffler H, Carlsson M, Hedlund M, Qian Y, Pointer F (2004) Introduction to galectins. Glycoconjug J 19:433–440.
71. Lefranç F, Brochi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23:2411–2422.
72. Lefranç F, James S, Camby I, Ourselin MF, Darro F, Brochi J et al (2005) Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U873 human glioblastoma multiforme orthotopic xenografts. J Neurosurg 102:706–714.
Galectins and Gliomas

Le Mercier et al

73. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R (2006) Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 6:719–732.

74. Lefranc F, Facchini V, Kiss R (2007) Proutophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12:1395–1403.

75. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29–41.

76. Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97–117.

77. Louis DN, Ogaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer (IARC): Lyon.

78. Maglott A, Bartik P, Cosgun S, Klotz P, Ronde P, Fuhrmann G (2006) The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res 66:6002–6007.

79. Mann MJ, Hendershot LM (2006) UPR activation alters chemosensitivity of tumor cells. Cancer Biol Ther 5:736–740.

80. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I et al (2007) Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127:2399–2410.

81. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, Raz A et al (2007) SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 419:172–177.

82. Megalizzi V, Mathieu V, Mijatovic T, Gaull P, Debeir O, De Neve N et al (2007) 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9:358–369.

83. Moiseeva EP, Spring EL, Baron JH, de Bono DP (1999) Galectin 1 modulates attachment, spreading and migration of cultured vascular smooth muscle cells via interactions with cellular receptors and components of extracellular matrix. J Vasc Res 36:47–58.

84. Moiseeva EP, Javed Q, Spring EL, de Bono DP (2000) Galectin 1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 45:493–502.

85. Moiseeva EP, Williams B, Goodall AH, Samani NJ (2003) Galectin-1 interacts with beta1 subunit of integrin. Biochem Biophys Res Commun 310:1010–1016.

86. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H et al (2002) Galectin-3 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50:392–401.

87. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64:458–478.

88. Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10:267–275.

89. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909.

90. Natarajan M, Hecker TP, Gladson CL (2003) Galectin-3 is an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol 14:399–405.

91. Nickel W (2003) The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem 270:2109–2119.

92. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A (1994) Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochem 33:14109–14114.

93. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

94. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

95. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

96. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

97. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

98. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

99. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

100. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

101. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

102. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

103. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

104. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

105. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

106. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

107. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

108. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

109. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

110. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

111. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

112. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

113. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

114. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

115. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

116. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.

117. Ochieng J, Leite-Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Cytokine Growth Factor Rev 9:73–80.
111. Saal I, Nagy N, Lensch M, Lohr M, Manning JC, Decaestecker C et al (2005) Human galectin-2: expression profiling by RT-PCR/immunohistochemistry and its introduction as a histochemical tool for ligand localization. Histol Histopathol 20:1191–1208.

112. Salatino M, Croci DO, Bianco GA, Ilarregui JM, Toscano MA, Rabinovich GA (2008) Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther 8:45–57.

113. Seelenmeyer C, Wegehingel S, Tews I, Kunzler M, Aebi M, Nickel W (2005) Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1. J Cell Biol 171:373–381.

114. Stillman BN, Mischel PS, Baum LG (2005) New roles for galectins in brain tumors–from prognostic markers to therapeutic targets. Clin Cancer Res 9:3080–3097.

115. Strik HM, Deininger MH, Frank B, Schluesener HJ, Meyermann R (2001) Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol 53:13–20.

116. Strik HM, Schmidt K, Lingor P, Tonges L, Kugler W, Nitsche M et al (2007) Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 18:483–488.

117. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J et al (2003) Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9:3080–3097.

118. Tews DS (2000) Adhesive and invasive features in gliomas. Pathol Res Pract 196:701–711.

119. Tews DS, Nissen A (1998) Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis 18:271–284.

120. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454.

121. Uhm JH, Gladson CL, Rao JS (1999) The role of integrins in the malignant phenotype of gliomas. Front Biosci 4:D188–99.

122. Vladimirova V, Waha A, Luckerath K, Pesheva P, Probstmeier R (2008) Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J Neurosci Res 86:2450–2461.

123. Wang D, Anderson JC, Gladson CL (2005) The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol 15:318–326.

124. Wen Y, Makagiansar IT, Fukushima J, Liu FT, Fukuda MN, Stallcup WB (2006) Molecular basis of interaction between NG2 proteoglycan and galectin-3. J Cell Biochem 98:115–127.

125. Zhou J, Schmid T, Schnitzer S, Brune B (2006) Tumor hypoxia and cancer progression. Cancer Lett 237:10–21.